WO2024117389A1 - Composition pharmaceutique pour la prévention ou le traitement de la démence sénile, et son procédé de préparation - Google Patents
Composition pharmaceutique pour la prévention ou le traitement de la démence sénile, et son procédé de préparation Download PDFInfo
- Publication number
- WO2024117389A1 WO2024117389A1 PCT/KR2023/003269 KR2023003269W WO2024117389A1 WO 2024117389 A1 WO2024117389 A1 WO 2024117389A1 KR 2023003269 W KR2023003269 W KR 2023003269W WO 2024117389 A1 WO2024117389 A1 WO 2024117389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dementia
- preventing
- vinegar
- weight
- licorice
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 18
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 239000000052 vinegar Substances 0.000 claims abstract description 33
- 235000021419 vinegar Nutrition 0.000 claims abstract description 33
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 28
- 210000004712 air sac Anatomy 0.000 claims abstract description 25
- 238000010438 heat treatment Methods 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 206010012289 Dementia Diseases 0.000 claims description 40
- 241000202807 Glycyrrhiza Species 0.000 claims description 29
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 29
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 29
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 29
- 229940010454 licorice Drugs 0.000 claims description 29
- 241000219061 Rheum Species 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000011874 heated mixture Substances 0.000 claims description 7
- 235000004936 Bromus mango Nutrition 0.000 claims description 6
- 240000007228 Mangifera indica Species 0.000 claims description 6
- 235000014826 Mangifera indica Nutrition 0.000 claims description 6
- 235000009184 Spondias indica Nutrition 0.000 claims description 6
- 208000013677 cerebrovascular dementia Diseases 0.000 claims description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract description 2
- 235000004385 Conyza canadensis Nutrition 0.000 abstract 1
- 241001252573 Erigeron canadensis Species 0.000 abstract 1
- 244000193032 Rheum rhaponticum Species 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 9
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 7
- 229950006874 kainic acid Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 238000010306 acid treatment Methods 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 3
- 206010009346 Clonus Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000001045 lordotic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241001609213 Carassius carassius Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000960945 Rheum coreanum Species 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 241001417494 Sciaenidae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- IPQVTOJGNYVQEO-CXZNLNCXSA-N sennoside A Natural products O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O5)cccc34)c2c1 IPQVTOJGNYVQEO-CXZNLNCXSA-N 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052600 sulfate mineral Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Definitions
- the present invention relates to a composition for preventing or improving dementia and a method for producing the same.
- Alzheimer's disease is the most important disease among senile dementias, and the accumulation of beta-amyloid in the brain and the resulting neurotoxicity are known to be important causes (ProbstA et al, Brain Pathol, 1:229-239, 1991).
- beta-amyloid is known to create plaques in which proteins accumulate and tangle in the brain, which causes Alzheimer's disease (Breimer LH, et alNature, 326: 749-750, 1987).
- beta-amyloid is made from amyloid precursor protein (APP) through the sequential action of beta-secretase (BACE1) and gamma-secretase, which are membrane protein hydrolases.
- BACE1 beta-secretase
- gamma-secretase membrane protein hydrolases.
- This beta-amyloid can be broadly divided into two types: A ⁇ 40 and A ⁇ 42, which consist of 40 or 42 amino acids.
- a ⁇ 40 accounts for the majority, but A ⁇ 42, which is produced in relatively small quantities, is pointed out as the most important pathogen because it easily creates plaques (Selkoe, Science 298: 789-891, 2002).
- tacrine Cognex, 1994
- donepezil Aricept, 1996)
- the mechanism of action of the above drugs is to prevent dementia by increasing the concentration of acetylcholine, a neurotransmitter, by inhibiting the activity of the enzyme acetylcholinesterase (AChE), an enzyme that decomposes acetylcholine, which plays a central role in the central nervous system. and is known to treat.
- AChE acetylcholinesterase
- tacrine is expensive compared to its efficacy and has the problem of serious hepatotoxicity
- donecortex has no hepatotoxicity, but stimulates the parasympathetic nerves and is known to have various side effects such as vomiting, nausea, and diarrhea.
- the purpose of the present invention is to provide a pharmaceutical composition for preventing or ameliorating dementia, comprising as an active ingredient a heated mixture of Beopje Manchuria, licorice, rhubarb, swim bladder, and vinegar.
- Another object of the present invention is to provide a health functional food for the prevention or improvement of dementia containing as an active ingredient a heated mixture of Beopje Mancho, licorice, rhubarb, swim bladder and vinegar.
- Another object of the present invention is to provide a method for producing a composition for preventing or improving dementia containing as an active ingredient a heated mixture of Beopje Mancho, licorice, rhubarb, swim bladder, and vinegar.
- composition for preventing or ameliorating dementia of the present invention for achieving the above object is characterized by containing as an active ingredient a heated mixture of Beopje mango, licorice, rhubarb, swim bladder, and vinegar.
- the mixing ratio of the above-mentioned seaweed, licorice, rhubarb, swim bladder and vinegar is 20 to 50 parts by weight, 10 to 50 parts by weight of licorice, 10 to 50 parts by weight of rhubarb, and 50 to 100 parts by weight of vinegar, based on 100 parts by weight of the swim bladder. It is characterized by denial.
- the dementia is characterized as one or more diseases selected from the group consisting of Alzheimer's dementia, cerebrovascular dementia, and dementia caused by senile dementia.
- the method for producing a composition for preventing or improving dementia of the present invention includes the steps of adding water to licorice, rhubarb and swim bladder and heating them, adding vinegar to the heated water and heating it, and the vinegar It is characterized in that it includes the step of adding and heating the added heating material.
- composition for preventing or improving dementia according to the present invention is stable as it does not cause toxicity to cells, and can inhibit the production of beta-amyloid, a known causative agent of dementia, especially Alzheimer's disease, thereby preventing dementia.
- beta-amyloid a known causative agent of dementia, especially Alzheimer's disease, thereby preventing dementia.
- it has the advantage of being able to be effectively used in treatment.
- Test Example 1 is a graph showing the results of Test Example 1 according to the present invention.
- Figure 2 is a graph showing the results of Test Example 2 according to the present invention.
- Figures 3 and 4 are graphs showing the results of Test Example 3 according to the present invention.
- dementia in general, refers to a disease in which a normal intellectual level is maintained during the growth period, but cognitive function impairment and personality changes occur later. Dementia is caused by the destruction of cranial nerves due to various causes, resulting in overall mental dysfunction such as memory impairment, language impairment, fecal incontinence, paranoid thinking, and aphasia. In the process, psychiatric symptoms such as depression, personality disorder, and aggression appear. It is also accompanied by The medical community is paying attention to the causal factors caused by aging and genetics, but the exact cause and treatment have not yet been identified. Diseases classified as dementia are not limited to this, but may include any one of Alzheimer's dementia, cerebrovascular dementia, and senile dementia, and the composition provided by the present invention is a disease that can be treated, prevented, and improved. It can be included.
- composition for preventing or improving dementia contains as an active ingredient a heated mixture of Beopje mango, licorice, rhubarb, swim bladder, and vinegar, and beta-amyloid, which is known to be a cause of dementia due to the interaction of each ingredient. By suppressing its production, it prevents or improves dementia, is good for the kidneys, and clears the mind.
- the Beopje Mango is a refined product of the sulfate mineral Mango, and mainly contains sodium sulfate.
- bakcho the first crystals that precipitate
- beopje mangcho the crystals obtained by repeated recrystallization
- Beopje Mangcho has been used for many symptoms of constipation.
- the Beopje Mangcho also has an analgesic effect.
- the legume decoction can be purchased and used commercially.
- the licorice (Glycyrrhiza uralensis) is a perennial herb belonging to the legume family and is grown or grown in northern China, Siberia, southern Italy, Manchuria, and Mongolia. Licorice is used as an ingredient to reduce toxicity in all herbal medicine prescriptions and is one of the herbs used as an antitussive (Rauchensteiner F. et al., JPharmBiomedAnal., 38(4), pp.594-600, 2005), and in Europe, it is used in tobacco, gum, and It is also used to sweeten candies. Recent research results show that licorice alleviates oxidative damage to the kidneys (Yokozawa T.
- licorice can be purchased and used commercially, or collected or cultivated directly from nature, and is not limited thereto. Additionally, there is no limitation as to whether or not it is dried.
- the rhubarb (Rhei Rhizoma) is the root and rhizome of Janggun, a perennial herb belonging to the Rhizoma family, and its close relatives. There are about 15 species of plants, including Rheum coreanum Nakail and Pheum undulatumLinne in Korea. In China, the dried roots and rhizomes of Rheum palmatum Linne, Pheum tanguticum Maxim, and medicinal rhubarb (Rheum offcinale Baill) are its origin. there is.
- Rhubarb is also clinically applied to the treatment of indigestion, constipation, acute inflammation, infectious diseases, parasitic diseases, bleeding, thrombocytopenia, burns, and skin diseases. It is also very effective in treating boils and phlegm.
- the rhubarb can be purchased and used commercially, or collected or cultivated directly from nature, and is not limited thereto. Additionally, there is no limitation as to whether or not it is dried.
- the swim bladder refers to an air sac in a fish, and is used as a raw material for isinlass, a high-quality glue. In the present invention, it is most preferable to use a croaker swim bladder as the swim bladder, but this is not necessarily limited.
- the vinegar is a fermented food that has been used since ancient times regardless of the East or West. It contains over 60 types of organic acids and is effective in relieving fatigue, preventing adult diseases, and increasing appetite.
- the type of vinegar is not limited, and any commercially available vinegar can be purchased and used.
- the mixing ratio of the legal mantra, licorice, rhubarb, swim bladder and vinegar is 20 to 50 parts by weight of legal mantra, 10 to 50 parts by weight of licorice, 10 to 50 parts by weight of rhubarb, and 50 to 50 parts by weight of vinegar, based on 100 parts by weight of the swim bladder. It is preferable that it is 100 parts by weight, because this ratio can show the best effect in preventing or improving dementia.
- composition of the present invention may be a pharmaceutical composition, and the composition may contain the above-described mixed powder alone, or may include one or more pharmaceutically acceptable carriers, excipients, or diluents.
- the pharmaceutically effective amount of the mixed powder is 0.5 to 100 mg/day/kg of body weight, preferably 0.5 to 5 mg/day/kg of body weight.
- the pharmaceutically effective amount may vary appropriately depending on the degree of dementia symptoms, the patient's age, weight, health status, gender, administration route, and treatment period.
- pharmaceutically acceptable as used herein refers to a composition that is physiologically acceptable and does not usually cause gastrointestinal disorders, allergic reactions such as dizziness, or similar reactions when administered to humans.
- the carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Examples include polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be additionally included.
- compositions of the present invention can be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the dosage form may be in any of the following forms: powder, granule, tablet, pill, emulsion, syrup, or soft or hard gelatin capsule.
- composition according to the present invention is preferably administered orally, and the dosage of the active ingredient may be appropriately selected depending on various factors such as the route of administration, the patient's age, gender, weight, and patient's severity.
- composition for preventing or improving dementia of the present invention can be added to food for the purpose of preventing or improving dementia symptoms, so the composition of the present invention can be used as a food composition for preventing or improving dementia symptoms.
- the food composition for preventing and improving dementia of the present invention can be easily used as a food effective in preventing or improving dementia symptoms, such as a main ingredient, secondary ingredient, food additive, functional food or beverage.
- Foods to which the composition for preventing and improving dementia symptoms according to the present invention can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, functional foods, etc. Additionally, foods in the present invention include special nutritional foods (e.g., infant formula, infant and toddler food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), breads, health supplements, and seasonings. Food (e.g. soy sauce, soybean paste, red pepper paste, mixed paste, etc.), sauces, confectionery (e.g. snacks), candy, chocolate, gum, ice cream, dairy products (e.g.
- special nutritional foods e.g., infant formula, infant and toddler food, etc.
- processed meat products e.g., fish products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), breads, health supplements, and seasonings.
- Food e.g. soy sauce, soybean paste, red pepper paste, mixed paste
- fermented milk, cheese, etc. other processed foods, kimchi, It includes, but is not limited to, pickled foods (various kimchi, pickled vegetables, etc.), beverages (e.g., fruit drinks, vegetable drinks, soy milk, fermented drinks, etc.), and natural seasonings (e.g., ramen soup, etc.).
- pickled foods various kimchi, pickled vegetables, etc.
- beverages e.g., fruit drinks, vegetable drinks, soy milk, fermented drinks, etc.
- natural seasonings e.g., ramen soup, etc.
- the food, beverage or food additive can be manufactured by conventional manufacturing methods.
- the above-mentioned functional food refers to a food group or food composition in which added value is added to the food to function and express the function of the food for a specific purpose using physical, biochemical, biotechnological methods, etc., and the regulation of biological defense rhythm, disease prevention and recovery. It refers to food that has been designed and processed to fully express the body's regulatory functions related to the body, etc., and may specifically be a health functional food.
- the functional food may include food auxiliary additives that are foodologically acceptable, and may further include appropriate carriers, excipients, and diluents commonly used in the production of functional foods.
- the amount of the composition according to the present invention may be 0.001% by weight to 100% by weight of the total weight of the food.
- the method for producing the composition according to the present invention includes the steps of adding water to licorice, rhubarb, and swim bladder and heating them, adding vinegar to the heated product and heating it, and adding a legal agent to the heated product to which the vinegar has been added. It is characterized in that it includes the step of adding peppermint and heating it.
- vinegar is added to the heated product and heated again at 80-100°C for 10-20 minutes.
- composition prepared as described above can be taken as is, or can be formulated and taken. At this time, additional formulation methods are not limited.
- the solid matter in the heated product to which the legal mango is added is pulverized to about 100 to 300 msh, and then dried. At this time, the drying method is not limited.
- the reason for drying after pulverizing in the present invention is to consider the material characteristics of bladders, etc., and because it is difficult to powder when pulverizing after drying.
- composition prepared as described above is in powder form and can be taken as is, or can be formulated into pills, liquids, etc., and the method of further formulation is not limited.
- the amount of each material used is preferably 20 to 50 parts by weight of Beopje Mancho, 10 to 50 parts by weight of licorice, 10 to 50 parts by weight of rhubarb, and 50 to 100 parts by weight of vinegar, based on 100 parts by weight of swim bladder. This is to increase prevention and improvement effects.
- composition of the present invention has the advantage of being effective in treating or preventing not only dementia but also epilepsy.
- the above-described heated product was pulverized so that the solid content in the heated product was approximately 200 mesh, and then freeze-dried to obtain a powder form.
- HeLa cell lines transfected with human-derived amyloid precursor protein (APP) were cultured in DMEM medium (Cat # 11995, Gibco, USA). used.
- the sample was added to the cell culture medium in which the cell line was cultured, then cultured at 37°C for 8 hours, and the amount of beta-amyloid secreted in the culture medium was measured.
- the Human ⁇ -Amyloid[1-42] (A ⁇ 42) Colorimetric ELISA kit (#KHB3442; BioSource International, Inc, USA) was used. And the results are shown in Figure 1. The case where the sample was not treated was used as the control group.
- Example 1 was found to inhibit A ⁇ 42 in a concentration-dependent manner.
- the known MTT Cell Proliferation assay method was used. Specifically, samples of various concentrations were treated with HeLa cells cultured in the same manner as Test Example 1 for 8 hours, and then viable cells were quantified, and the results are shown in FIG. 2. The case where the sample was not treated was used as the control group.
- Example 1 confirmed that cells almost did not die even when administered at a concentration of 5 ⁇ g/ml, confirming that it was safe for the human body. In addition, it was confirmed that the inhibition of A ⁇ 42 in Test Example 1 was not caused by apoptosis.
- the experimental animals were male ICR mice (10 weeks old, 34 to 36 g,) adjusted to a temperature of 23 ⁇ 1°C, humidity of 60 ⁇ 10%, 12 hours of day and night, and acclimatized in an animal room for 7 days with sufficient water and regular diet. It was used in subsequent experiments.
- the composition of Example 1 was orally administered at 100 mg/kg five times a day for three days, and on the third day of drug administration, 0.4 ⁇ g of kainic acid was directly injected into the lateral ventricle of the brain to induce epilepsy.
- Example 1 of the present invention an animal model in which epilepsy was induced by kainic acid was used to confirm the effects of delaying the seizure latency and reducing the frequency of seizures caused by the treatment in Example 1 of the present invention.
- stage 1 Behavioral seizure stages are identified into five stages: stage 1; facial movement, level 2; head nodding and myoclonic twitching, stage 3; forelimb clonus with lordotic posture, level 4; forelimb clonus with reared posture, level 5; There is a behavioral type of tonic-clonic seizure without postural control.
- stage 3 forelimb clonus with lordotic posture
- stage 3 seizure behavior occurred after kainic acid treatment was determined. It was recorded.
- Rats treated with kainic acid were videotaped for 6 hours to measure the seizure onset time caused by kainic acid treatment, and through this, the effect of delaying the latency of seizure onset by the treatment in Example 1 was confirmed. observed.
- SRS Spontaneous recurrent seizures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
La présente invention concerne une composition pour la prévention ou l'amélioration de la démence sénile, et son procédé de préparation. Plus spécifiquement, la composition contient une substance chauffée, obtenue par mélange et chauffage d'Erigeron Canadensis détoxifié, de Glycyrrhiza uralensis, de Rheum rhabarbarum, de vessie à air et de vinaigre, en tant que principe actif. Selon la présente invention, la composition ne provoque pas de toxicité dans les cellules, est donc stable, peut éliminer la production de bêta-amyloïde, connue comme étant une cause de la démence sénile, en particulier de la maladie d'Alzheimer, et présente ainsi l'avantage d'être efficace pour prévenir ou traiter la démence sénile.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2022-0162119 | 2022-11-29 | ||
KR1020220162119A KR102532914B1 (ko) | 2022-11-29 | 2022-11-29 | 치매 예방 또는 개선용 조성물 및 그 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024117389A1 true WO2024117389A1 (fr) | 2024-06-06 |
Family
ID=86545219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2023/003269 WO2024117389A1 (fr) | 2022-11-29 | 2023-03-09 | Composition pharmaceutique pour la prévention ou le traitement de la démence sénile, et son procédé de préparation |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102532914B1 (fr) |
WO (1) | WO2024117389A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050008598A (ko) * | 2001-06-15 | 2005-01-21 | 주식회사 장생도라지 | 도라지 추출물을 포함하는 퇴행성 뇌질환의 예방 및치료용 또는 기억력 증진용 약학 조성물 |
KR20150067902A (ko) * | 2013-12-10 | 2015-06-19 | 주식회사한국전통의학연구소 | 데속소-나치놀 A 및 8α-하이드록시피노레시놀을 유효성분으로 함유하는 패혈증 예방 및 치료용 약학적 조성물 |
WO2017104706A1 (fr) * | 2015-12-18 | 2017-06-22 | 国立大学法人 富山大学 | Agent et composition pour induire l'expression du facteur neurotrophique dérivé du cerveau |
KR102138348B1 (ko) * | 2020-04-24 | 2020-07-28 | 권혁분 | 뇌전증의 예방 또는 치료용 조성물 및 그 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101404566B1 (ko) | 2012-11-09 | 2014-06-11 | 동아대학교 산학협력단 | 갈색거저리 추출물을 포함하는 치매 예방 또는 치료용 조성물 |
KR101840451B1 (ko) | 2017-09-07 | 2018-03-22 | 재단법인 통합의료진흥원 | 육미지황탕을 포함하는 치매 치료용 조성물 |
-
2022
- 2022-11-29 KR KR1020220162119A patent/KR102532914B1/ko active IP Right Grant
-
2023
- 2023-03-09 WO PCT/KR2023/003269 patent/WO2024117389A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050008598A (ko) * | 2001-06-15 | 2005-01-21 | 주식회사 장생도라지 | 도라지 추출물을 포함하는 퇴행성 뇌질환의 예방 및치료용 또는 기억력 증진용 약학 조성물 |
KR20150067902A (ko) * | 2013-12-10 | 2015-06-19 | 주식회사한국전통의학연구소 | 데속소-나치놀 A 및 8α-하이드록시피노레시놀을 유효성분으로 함유하는 패혈증 예방 및 치료용 약학적 조성물 |
WO2017104706A1 (fr) * | 2015-12-18 | 2017-06-22 | 国立大学法人 富山大学 | Agent et composition pour induire l'expression du facteur neurotrophique dérivé du cerveau |
KR102138348B1 (ko) * | 2020-04-24 | 2020-07-28 | 권혁분 | 뇌전증의 예방 또는 치료용 조성물 및 그 제조방법 |
Non-Patent Citations (1)
Title |
---|
LEE BONG HO, CHOI BYOUNG WOOK, RYU GEON SEEK, LEE EUN SEOG, KANG KYE JUNG, HWANG DHO YEUN, HONG NAM DOO: "Screening of the Acetylcholinesterase inhibitors from Medicinal Plants Bong Ho Lee,", KOREAN JOURNAL OF PHARMACOGNOSY, vol. 28, no. 4, 1 January 1997 (1997-01-01), pages 167 - 173, XP093177339 * |
Also Published As
Publication number | Publication date |
---|---|
KR102532914B1 (ko) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101875307B1 (ko) | 복합 생약 추출물을 함유하는 수면 증진 또는 개선용 조성물 및 이의 용도 | |
WO2021215598A1 (fr) | Composition pour la prévention ou le traitement de l'épilepsie et son procédé de préparation | |
JP6773821B2 (ja) | 桑椹子およびブクリョウ皮の混合抽出物を含有する退行性神経疾患の予防、改善または治療用組成物 | |
KR102227186B1 (ko) | 사간 추출물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
KR102002298B1 (ko) | 생약 추출물을 포함하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 | |
KR101690175B1 (ko) | 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물 | |
WO2024117389A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de la démence sénile, et son procédé de préparation | |
WO2022203251A1 (fr) | Composition complexe pour la prévention ou le traitement de la perte auditive contenant du sarpogrelate et un extrait de vaccinium myrtillus en tant que principes actifs | |
KR20080008929A (ko) | 오록실린 a를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품 | |
KR101987418B1 (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 뇌신경 보호용 조성물 | |
WO2014133286A1 (fr) | Composition contenant des extraits d'artemisia iwayomogi et de curcuma longa en tant que principes actifs pour la prévention, l'inhibition ou le traitement de maladies se rapportant à l'obésité | |
KR20110029714A (ko) | 치매 예방 또는 치료용 조성물 | |
KR101748301B1 (ko) | 질경이 추출물 및 인삼 추출물을 포함하는 퇴행성 뇌질환의 예방, 개선 및 치료용 조성물 | |
KR101862032B1 (ko) | 향부자 추출물 및 이의 분획물로부터 분리된 스키르푸신 a와 b를 유효성분으로 함유하는 퇴행성 뇌질환 및 스트레스성 질환의 예방 또는 치료용 조성물 | |
WO2019103248A1 (fr) | Composition pour prévenir ou traiter l'athérosclérose, contenant un extrait de dystaenia takeshimana | |
WO2015122728A1 (fr) | Composition anti-tuberculose pour le traitement et la prévention de la tuberculose comprenant un extrait ou de melia azedarach l. ou un extrait de lobelia chinensis lour et des fractions de ceux-ci | |
KR20150113434A (ko) | 인삼씨 추출물을 포함하는 뇌신경세포 보호 및 우울증의 예방, 개선 및 치료용 조성물 | |
KR102664506B1 (ko) | 지실 및 죽엽 혼합물을 유효성분으로 함유하는 장기능 개선용 조성물 | |
KR20200089527A (ko) | 석창포 및 황칠 혼합 추출물을 포함하는 항염증용 조성물 | |
KR102429285B1 (ko) | 천마복합처방을 포함하는 뇌신경질환의 예방, 개선 또는 치료용 조성물 | |
WO2022010290A1 (fr) | Composition comprenant un extrait de graine de radis enrichi en sulforaphène et sa méthode de préparation | |
KR102555302B1 (ko) | 히비스커스, 로즈마리, 및 포도씨 추출물을 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료 조성물 | |
KR101924711B1 (ko) | 갈수를 유효성분으로 포함하는 건망증 치료, 예방 및 개선용 조성물 | |
KR20240026350A (ko) | 치매 예방 또는 개선용 조성물 | |
WO2022097794A1 (fr) | Composition pour la prévention ou le traitement de la cachexie, contenant un extrait complexe de salviae miltiorrhizae radix et de rhei radix et rhizoma |